JP5221552B2 - Ｃ型肝炎ウイルス阻害剤としての大環状ペプチド - Google Patents

Ｃ型肝炎ウイルス阻害剤としての大環状ペプチド Download PDF

Info

Publication number
JP5221552B2
JP5221552B2 JP2009537356A JP2009537356A JP5221552B2 JP 5221552 B2 JP5221552 B2 JP 5221552B2 JP 2009537356 A JP2009537356 A JP 2009537356A JP 2009537356 A JP2009537356 A JP 2009537356A JP 5221552 B2 JP5221552 B2 JP 5221552B2
Authority
JP
Japan
Prior art keywords
tert
mmol
alkyl
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009537356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510233A (ja
JP2010510233A5 (cg-RX-API-DMAC7.html
Inventor
ワン・アラン・シャンドン
バーバラ・ジジェン・ジェン
スタンリー・ダンドレア
ニコラス・エイ・ミーンウェル
ポール・マイケル・スコーラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2010510233A publication Critical patent/JP2010510233A/ja
Publication of JP2010510233A5 publication Critical patent/JP2010510233A5/ja
Application granted granted Critical
Publication of JP5221552B2 publication Critical patent/JP5221552B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009537356A 2006-11-16 2007-11-15 Ｃ型肝炎ウイルス阻害剤としての大環状ペプチド Expired - Fee Related JP5221552B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86612506P 2006-11-16 2006-11-16
US60/866,125 2006-11-16
US11/939,768 2007-11-14
US11/939,768 US7763584B2 (en) 2006-11-16 2007-11-14 Hepatitis C virus inhibitors
PCT/US2007/084788 WO2008064061A1 (en) 2006-11-16 2007-11-15 Macrocyclic peptides as hepatitis c virus inhibitors

Publications (3)

Publication Number Publication Date
JP2010510233A JP2010510233A (ja) 2010-04-02
JP2010510233A5 JP2010510233A5 (cg-RX-API-DMAC7.html) 2011-01-06
JP5221552B2 true JP5221552B2 (ja) 2013-06-26

Family

ID=39245073

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009537356A Expired - Fee Related JP5221552B2 (ja) 2006-11-16 2007-11-15 Ｃ型肝炎ウイルス阻害剤としての大環状ペプチド

Country Status (7)

Country Link
US (1) US7763584B2 (cg-RX-API-DMAC7.html)
EP (1) EP2086980B1 (cg-RX-API-DMAC7.html)
JP (1) JP5221552B2 (cg-RX-API-DMAC7.html)
AT (1) ATE492558T1 (cg-RX-API-DMAC7.html)
DE (1) DE602007011488D1 (cg-RX-API-DMAC7.html)
NO (1) NO20091845L (cg-RX-API-DMAC7.html)
WO (1) WO2008064061A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
NZ587133A (en) 2008-02-04 2012-10-26 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitor compounds for treating an HCV infection
US7964560B2 (en) * 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) * 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2740728A1 (en) * 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
US8283310B2 (en) * 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2758072A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
WO2011041551A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
JP2013173677A (ja) * 2010-06-15 2013-09-05 Kaneka Corp （１ｒ，２ｓ）−１−アミノ−２−ビニルシクロプロパンカルボン酸エステルの製造法
US20120095211A1 (en) * 2010-09-22 2012-04-19 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
JP5918264B2 (ja) 2010-12-22 2016-05-18 アッヴィ・インコーポレイテッド Ｃ型肝炎阻害剤およびその使用
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2903988A1 (en) 2012-10-08 2015-08-12 AbbVie Inc. Compounds useful for making hcv protease inhibitors
DK2909205T3 (en) 2012-10-19 2017-03-06 Bristol Myers Squibb Co 9-METHYL-SUBSTITUTED HEXADECAHYDROCYCLOPROPA (E) PYRROL (1,2-A) (1,4) DIAZOCYCLOPENTADECINYLCARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR TREATMENT
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475255A3 (en) 1990-09-12 1993-04-14 F. Hoffmann-La Roche Ag Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid
EA001915B1 (ru) 1996-10-18 2001-10-22 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы серин-протеаз, в частности ns3 протеазы вируса гепатита c (hvc)
DK1003775T3 (da) 1997-08-11 2005-05-30 Boehringer Ingelheim Ca Ltd Hepatitis C-inhibitorpeptider
AU757072B2 (en) 1997-08-11 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptide analogues
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
JP3889708B2 (ja) 2000-11-20 2007-03-07 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎トリペプチド阻害剤
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
ES2350201T3 (es) 2002-05-20 2011-01-20 Bristol-Myers Squibb Company Sulfamidas heterocíclicas como inhibidores del virus de la hepatitis c.
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
PL215228B1 (pl) 2002-05-20 2013-11-29 Bristol Myers Squibb Co Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie
US20060199773A1 (en) 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
WO2004043339A2 (en) 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
EP1590442A4 (en) 2003-02-07 2007-07-18 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
WO2004101605A1 (en) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
CA2516018C (en) 2003-03-05 2011-08-23 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
UA81028C2 (en) 2003-04-02 2007-11-26 Boehringer Ingelheim Int Pharmaceutical compositions for hepatitis c viral protease inhibitors
DE602004019518D1 (de) 2003-04-16 2009-04-02 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
EP2143727B1 (en) 2003-04-18 2015-01-21 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
EP1654261B1 (en) 2003-05-21 2007-11-14 Boehringer Ingelheim International GmbH Hepatitis c inhibitor compounds
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
DE602004031645D1 (de) 2003-09-22 2011-04-14 Boehringer Ingelheim Pharma Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
US20050070955A1 (en) 2003-09-30 2005-03-31 Codman & Shurtleff, Inc. Articulable forceps
CA2541634A1 (en) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
RS20060259A (sr) 2003-10-14 2008-08-07 Intermune Inc., Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005051980A1 (en) 2003-11-20 2005-06-09 Schering Corporation Depeptidized inhibitors of hepatitis c virus ns3 protease
WO2005070955A1 (en) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
HRP20100048T1 (hr) 2004-01-30 2010-04-30 Medivir Ab Inhibitori hcv ns-3 serin proteaze
CA2560897C (en) 2004-03-30 2012-06-12 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2006016930A2 (en) 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
EP1753775B1 (en) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
US7705146B2 (en) 2004-06-28 2010-04-27 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor peptide analogs
US20080311077A1 (en) 2004-07-16 2008-12-18 Kleem Chaudhary Antiviral Compounds
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
WO2006007708A1 (en) 2004-07-20 2006-01-26 Boehringer Engelheim International Gmbh Hepatitis c inhibitor peptide analogs
MX2007002371A (es) 2004-08-27 2007-04-23 Schering Corp Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
JP2008513454A (ja) 2004-09-17 2008-05-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状ｈｃｖプロテアーゼインヒビターの調製方法
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
BRPI0517463A (pt) 2004-10-21 2008-10-07 Pfizer inibidores da protease do vìrus da hepatite c, composições e tratamentos usando os mesmos
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5667745B2 (ja) 2005-03-08 2015-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状化合物を製造する方法
CA2606195C (en) 2005-05-02 2015-03-31 Merck And Co., Inc. Hcv ns3 protease inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006130687A2 (en) 2005-06-02 2006-12-07 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor
PE20070011A1 (es) 2005-06-02 2007-03-08 Schering Corp Formulaciones farmaceuticas de compuestos inhibidores de proteasa del vhc o catepsina
WO2006130552A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
US20060287248A1 (en) 2005-06-02 2006-12-21 Schering Corporation Asymmetric dosing methods
WO2006130554A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
US20060276405A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis C
AU2006252519B2 (en) 2005-06-02 2012-08-30 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
WO2006130666A2 (en) 2005-06-02 2006-12-07 Schering Corporation Medicaments and methods combining a hcv protease inhibitor and an akr competitor
US20070004635A1 (en) 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
US20060281689A1 (en) 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
EP1898941A2 (en) 2005-06-02 2008-03-19 Schering Corporation Controlled-release formulation useful for treating disorders associated with hepatitis c virus
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
JP2009501732A (ja) 2005-07-20 2009-01-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
EP2305697A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
DK1912996T3 (da) 2005-07-29 2012-09-17 Janssen R & D Ireland Makrocykliske inhibitorer af hepatitis C-virus
EP1919904B1 (en) 2005-07-29 2014-01-08 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis c virus
JP5230415B2 (ja) 2005-07-29 2013-07-10 テイボテク・フアーマシユーチカルズ Ｃ型肝炎ウイルスの大員環状阻害剤
RU2419619C2 (ru) 2005-07-29 2011-05-27 Медивир Аб Макроциклические ингибиторы вируса гепатита с
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
SI1919898T1 (sl) 2005-07-29 2011-05-31 Tibotec Pharm Ltd Makrociklični inhibitorji virusa hepatitisa C
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
TW200745061A (en) 2005-07-29 2007-12-16 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis C virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
ES2449540T3 (es) 2005-07-29 2014-03-20 Janssen R&D Ireland Inhibidores macrocíclicos del virus de la hepatitis C
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
WO2007016476A2 (en) 2005-08-01 2007-02-08 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
US8278322B2 (en) 2005-08-01 2012-10-02 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CA2624333A1 (en) 2005-10-11 2007-04-19 Intermune, Inc. Compounds and methods for inhibiting hepatitis c viral replication
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2007082131A1 (en) 2006-01-09 2007-07-19 Bristol-Myers Squibb Company Process for the preparation of hydroxy substituted heterocycles
CA2644389A1 (en) 2006-03-03 2007-09-20 Schering Corporation Pharmaceutical combinations of hcv-protease and -ires inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7605126B2 (en) 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US7582605B2 (en) 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors

Also Published As

Publication number Publication date
JP2010510233A (ja) 2010-04-02
DE602007011488D1 (de) 2011-02-03
WO2008064061A1 (en) 2008-05-29
NO20091845L (no) 2009-06-15
US7763584B2 (en) 2010-07-27
EP2086980B1 (en) 2010-12-22
ATE492558T1 (de) 2011-01-15
EP2086980A1 (en) 2009-08-12
US20080145334A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
JP5221552B2 (ja) Ｃ型肝炎ウイルス阻害剤としての大環状ペプチド
JP5241728B2 (ja) Ｃ型肝炎ウイルス阻害剤としての大環状ペプチド
JP5241729B2 (ja) Ｃ型肝炎ウイルス阻害剤
JP5450604B2 (ja) Ｃ型肝炎ウイルス阻害剤
JP5474940B2 (ja) Ｃ型肝炎ウイルス阻害剤
JP5487209B2 (ja) Ｃ型肝炎ウイルス阻害剤
JP4940231B2 (ja) Ｃ型肝炎ウイルスインヒビターとしてのトリペプチド
EP2813500B1 (en) Intermediates for the preparation of hepatitis C virus inhibitors
JP2012512169A (ja) Ｃ型肝炎ウイルス阻害剤
JP2010508361A (ja) Ｃ型肝炎ウイルスの阻害剤
JP2010508360A (ja) Ｃ型肝炎ウイルスの阻害剤
JP2010508362A (ja) Ｃ型肝炎ウイルスの阻害剤
WO2008008776A2 (en) Hepatitis c virus inhibitors
JP2011521911A (ja) Ｃ型肝炎ウイルス阻害剤
JP6110846B2 (ja) Ｃ型肝炎ウイルス阻害剤としての重水素が導入されたトリペプチド
JP2012511004A (ja) Ｃ型肝炎ウイルス阻害剤
ES2357494T3 (es) Péptidos macrocíclicos como inhibidores de la hepatitis c.
ES2356273T3 (es) Péptidos macrocíclicos como inhibidores del virus de la hepatitis c.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130307

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160315

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees